{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T05:46:51Z","timestamp":1790401611965,"version":"4.1.0"},"reference-count":48,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"vor","delay-in-days":1461,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["kidney-international.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1016\/j.kint.2016.10.039","type":"journal-article","created":{"date-parts":[[2017,1,16]],"date-time":"2017-01-16T20:23:38Z","timestamp":1484598218000},"page":"575-586","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":51,"title":["STAT5 drives abnormal proliferation in autosomal dominant polycystic kidney disease"],"prefix":"10.1016","volume":"91","author":[{"given":"Maria","family":"Fragiadaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgane","family":"Lannoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madeleine","family":"Themanns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Maurer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wouter N.","family":"Leonhard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorien J.M.","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Moriggl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert C.M.","family":"Ong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.kint.2016.10.039_bib1","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1016\/S0140-6736(15)60907-2","article-title":"Autosomal dominant polycystic kidney disease: the changing face of clinical management","volume":"385","author":"Ong","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.kint.2016.10.039_bib2","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/S0092-8674(00)81793-6","article-title":"The molecular basis of focal cyst formation in human autosomal dominant polycystic kidney disease type I","volume":"87","author":"Qian","year":"1996","journal-title":"Cell"},{"key":"10.1016\/j.kint.2016.10.039_bib3","doi-asserted-by":"crossref","first-page":"148","DOI":"10.2215\/CJN.00330705","article-title":"Volume progression in autosomal dominant polycystic kidney disease: the major factor determining clinical outcomes","volume":"1","author":"Grantham","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2016.10.039_bib4","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1681\/ASN.V115814","article-title":"Cellular and subcellular distribution of polycystin-2, the protein product of the PKD2 gene","volume":"11","author":"Foggensteiner","year":"2000","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2016.10.039_bib5","first-page":"1153","article-title":"Dysregulation of cellular proliferation and apoptosis mediates human autosomal dominant polycystic kidney disease (ADPKD)","volume":"13","author":"Lanoix","year":"1996","journal-title":"Oncogene"},{"key":"10.1016\/j.kint.2016.10.039_bib6","doi-asserted-by":"crossref","first-page":"803","DOI":"10.2215\/CJN.06300615","article-title":"Effect of tolvaptan in autosomal dominant polycystic kidney disease by CKD stage: results\u00a0from the TEMPO 3:4 Trial","volume":"11","author":"Torres","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2016.10.039_bib7","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1038\/nature04469","article-title":"Identification of pathways regulating cell size and cell-cycle progression by RNAi","volume":"439","author":"Bjorklund","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.kint.2016.10.039_bib8","doi-asserted-by":"crossref","first-page":"1249783","DOI":"10.1126\/science.1249783","article-title":"Mechanism of activation of protein kinase JAK2 by the growth hormone receptor","volume":"344","author":"Brooks","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.kint.2016.10.039_bib9","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0092-8674(02)00716-X","article-title":"PKD1 induces p21(waf1) and regulation of the cell cycle via direct activation of the JAK-STAT signaling pathway in a process requiring PKD2","volume":"109","author":"Bhunia","year":"2002","journal-title":"Cell"},{"key":"10.1016\/j.kint.2016.10.039_bib10","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.devcel.2005.12.005","article-title":"Polycystin-1, STAT6, and P100 function in a pathway that transduces ciliary mechanosensation and is activated in polycystic kidney disease","volume":"10","author":"Low","year":"2006","journal-title":"Dev Cell"},{"key":"10.1016\/j.kint.2016.10.039_bib11","doi-asserted-by":"crossref","first-page":"18067","DOI":"10.1073\/pnas.1111966108","article-title":"Signal transducer and activator of transcription-6 (STAT6) inhibition suppresses renal cyst growth in polycystic kidney disease","volume":"108","author":"Olsan","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.kint.2016.10.039_bib12","doi-asserted-by":"crossref","first-page":"7985","DOI":"10.1073\/pnas.1103816108","article-title":"Polycystin-1 regulates STAT activity by a dual mechanism","volume":"108","author":"Talbot","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.kint.2016.10.039_bib13","doi-asserted-by":"crossref","first-page":"F1193","DOI":"10.1152\/ajprenal.00419.2010","article-title":"Curcumin inhibits cystogenesis by simultaneous interference of multiple signaling pathways: in\u00a0vivo evidence from a Pkd1-deletion model","volume":"300","author":"Leonhard","year":"2011","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.kint.2016.10.039_bib14","doi-asserted-by":"crossref","first-page":"4143","DOI":"10.1093\/hmg\/ddr338","article-title":"Pyrimethamine inhibits adult polycystic kidney disease by modulating STAT signaling pathways","volume":"20","author":"Takakura","year":"2011","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.kint.2016.10.039_bib15","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/sj.ki.5002229","article-title":"Hyperproliferation of PKD1 cystic cells is induced by insulin-like growth factor-1 activation of the Ras\/Raf signalling system","volume":"72","author":"Parker","year":"2007","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2016.10.039_bib16","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1002\/cbic.200700701","article-title":"Discovery of chromone-based inhibitors\u00a0of the transcription factor STAT5","volume":"9","author":"Muller","year":"2008","journal-title":"Chembiochem"},{"key":"10.1016\/j.kint.2016.10.039_bib17","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.1093\/hmg\/ddh336","article-title":"Lowering of Pkd1 expression is sufficient to cause polycystic kidney disease","volume":"13","author":"Lantinga-van Leeuwen","year":"2004","journal-title":"Human Mol Genet"},{"key":"10.1016\/j.kint.2016.10.039_bib18","doi-asserted-by":"crossref","first-page":"3188","DOI":"10.1093\/hmg\/ddm299","article-title":"Kidney-specific inactivation of the Pkd1 gene induces rapid cyst formation in developing kidneys and a slow onset of disease in adult mice","volume":"16","author":"Lantinga-van Leeuwen","year":"2007","journal-title":"Human Mol Genet"},{"key":"10.1016\/j.kint.2016.10.039_bib19","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/0009-2797(76)90138-1","article-title":"The biosynthesis of metallothionein rat liver and kidney after administration of cadmium","volume":"15","author":"Shaikh","year":"1976","journal-title":"Chem Biol Interact"},{"key":"10.1016\/j.kint.2016.10.039_bib20","first-page":"222","article-title":"Metallothionein gene expression in rats: tissue-specific regulation by dietary copper and zinc","volume":"118","author":"Blalock","year":"1988","journal-title":"J\u00a0Nutr"},{"key":"10.1016\/j.kint.2016.10.039_bib21","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1002\/hep.24765","article-title":"Growth-hormone-induced signal transducer and activator of transcription 5 signaling\u00a0causes gigantism, inflammation, and premature death but protects mice from aggressive liver cancer","volume":"55","author":"Friedbichler","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.kint.2016.10.039_bib22","doi-asserted-by":"crossref","first-page":"8037","DOI":"10.1128\/MCB.24.18.8037-8047.2004","article-title":"Inactivation of Stat5 in mouse mammary epithelium during pregnancy reveals distinct functions in cell proliferation, survival, and differentiation","volume":"24","author":"Cui","year":"2004","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.kint.2016.10.039_bib23","doi-asserted-by":"crossref","first-page":"4754","DOI":"10.1093\/emboj\/18.17.4754","article-title":"STAT5 as a molecular regulator of proliferation, differentiation and apoptosis in hematopoietic cells","volume":"18","author":"Nosaka","year":"1999","journal-title":"EMBO J"},{"key":"10.1016\/j.kint.2016.10.039_bib24","doi-asserted-by":"crossref","first-page":"7239","DOI":"10.1073\/pnas.94.14.7239","article-title":"Requirement of STAT5b for sexual dimorphism of body growth rates and liver gene expression","volume":"94","author":"Udy","year":"1997","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.kint.2016.10.039_bib25","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1586\/17474086.2015.1074858","article-title":"The use of JAK inhibitors for low-risk myelofibrosis","volume":"8","author":"Alimam","year":"2015","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.kint.2016.10.039_bib26","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s13045-015-0192-7","article-title":"JAK kinase inhibitors for the treatment of acute lymphoblastic leukemia","volume":"8","author":"Degryse","year":"2015","journal-title":"J\u00a0Hematol Oncol"},{"key":"10.1016\/j.kint.2016.10.039_bib27","doi-asserted-by":"crossref","first-page":"409","DOI":"10.3324\/haematol.2015.124099","article-title":"JAK inhibitors and myelofibrosis, Einstein and ruxolitinib","volume":"100","author":"Harrison","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.kint.2016.10.039_bib28","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1093\/jb\/mvv069","article-title":"Recent progress and perspective in JAK inhibitors for rheumatoid arthritis: from bench to bedside","volume":"158","author":"Tanaka","year":"2015","journal-title":"J\u00a0Biochem"},{"key":"10.1016\/j.kint.2016.10.039_bib29","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1182\/asheducation-2009.1.636","article-title":"Therapeutic potential of JAK2 inhibitors","author":"Verstovsek","year":"2009","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.kint.2016.10.039_bib30","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.tcb.2008.08.008","article-title":"Canonical and non-canonical JAK-STAT signaling","volume":"18","author":"Li","year":"2008","journal-title":"Trends Cell Biol"},{"key":"10.1016\/j.kint.2016.10.039_bib31","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1021\/jm200720n","article-title":"Small molecule STAT5-SH2 domain inhibitors exhibit potent antileukemia activity","volume":"55","author":"Page","year":"2012","journal-title":"J\u00a0Med Chem"},{"key":"10.1016\/j.kint.2016.10.039_bib32","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.kint.2016.01.026","article-title":"Inhibition of histone deacetylase 6\u00a0activity reduces cyst growth in polycystic kidney disease","volume":"90","author":"Cebotaru","year":"2016","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2016.10.039_bib33","doi-asserted-by":"crossref","first-page":"3524","DOI":"10.1093\/nar\/gkv188","article-title":"Deacetylase inhibitors repress STAT5-mediated transcription by interfering with bromodomain and extra-terminal (BET) protein function","volume":"43","author":"Pinz","year":"2015","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.kint.2016.10.039_bib34","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1128\/MCB.22.1.117-126.2002","article-title":"Stat6 and IRS-2 cooperate in interleukin 4 (IL-4)-induced proliferation and differentiation but are dispensable for IL-4-dependent rescue from apoptosis","volume":"22","author":"Wurster","year":"2002","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.kint.2016.10.039_bib35","doi-asserted-by":"crossref","first-page":"e113","DOI":"10.1016\/j.ddmec.2013.03.001","article-title":"STAT3 Signaling in Polycystic Kidney Disease","volume":"10","author":"Weimbs","year":"2013","journal-title":"Drug Discov Today Dis Mech"},{"key":"10.1016\/j.kint.2016.10.039_bib36","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1054\/npep.2002.0889","article-title":"Consequences of growth hormone (GH) overexpression and GH resistance","volume":"36","author":"Bartke","year":"2002","journal-title":"Neuropeptides"},{"key":"10.1016\/j.kint.2016.10.039_bib37","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1093\/jnci\/82.5.393","article-title":"New murine model for hepatocellular carcinoma: transgenic mice expressing metallothionein-ovine growth hormone fusion gene","volume":"82","author":"Orian","year":"1990","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.kint.2016.10.039_bib38","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/BF01453693","article-title":"Accelerated growth and visceral\u00a0lesions in transgenic mice expressing foreign genes of the\u00a0growth hormone family: an overview","volume":"5","author":"Wanke","year":"1991","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.kint.2016.10.039_bib39","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1016\/j.leukres.2006.03.024","article-title":"Src transduces signaling via growth hormone (GH)-activated GH receptor (GHR) tyrosine-phosphorylating GHR and STAT5 in human leukemia cells","volume":"30","author":"Manabe","year":"2006","journal-title":"Leuk Res"},{"key":"10.1016\/j.kint.2016.10.039_bib40","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1210\/jc.2003-2133","article-title":"A\u00a0novel C-terminal growth hormone receptor (GHR) mutation results in impaired GHR-STAT5 but normal STAT-3 signaling","volume":"90","author":"Tiulpakov","year":"2005","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.kint.2016.10.039_bib41","first-page":"1249","article-title":"Identification of growth hormone\u00a0receptor (GHR) tyrosine residues required for GHR phosphorylation and JAK2 and STAT5 activation","volume":"10","author":"Wang","year":"1996","journal-title":"Mol Endocrinol"},{"key":"10.1016\/j.kint.2016.10.039_bib42","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1016\/S0140-6736(13)61407-5","article-title":"Effect of longacting somatostatin analogue on kidney and cyst growth in autosomal dominant polycystic kidney disease (ALADIN): a randomised, placebo-controlled, multicentre trial","volume":"382","author":"Caroli","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.kint.2016.10.039_bib43","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1210\/jcem-69-4-906","article-title":"The somatostatin analog octreotide inhibits the secretion of growth hormone (GH)-releasing hormone, thyrotropin, and GH in man","volume":"69","author":"Masuda","year":"1989","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.kint.2016.10.039_bib44","doi-asserted-by":"crossref","first-page":"2647","DOI":"10.1038\/sj.onc.1201789","article-title":"FGF signaling activates STAT1 and p21 and inhibits the estrogen response and proliferation of MCF-7 cells","volume":"16","author":"Johnson","year":"1998","journal-title":"Oncogene"},{"key":"10.1016\/j.kint.2016.10.039_bib45","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1038\/ki.2013.13","article-title":"Cyst expansion and regression in a mouse model of polycystic kidney disease","volume":"83","author":"Happe","year":"2013","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2016.10.039_bib46","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1073\/pnas.98.2.646","article-title":"Conditional immortalization of freshly isolated human mammary fibroblasts and endothelial cells","volume":"98","author":"O'Hare","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.kint.2016.10.039_bib47","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1681\/ASN.2013111179","article-title":"Inactivation of integrin-beta1 prevents the development of polycystic kidney disease after the loss of polycystin-1","volume":"26","author":"Lee","year":"2015","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2016.10.039_bib48","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/S0022-2143(97)90180-3","article-title":"Cell lines with extended in\u00a0vitro growth potential from human renal proximal tubule: characterization, response to inducers, and comparison with established cell lines","volume":"129","author":"Racusen","year":"1997","journal-title":"J\u00a0Lab Clin Med"}],"container-title":["Kidney International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S008525381630655X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S008525381630655X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,21]],"date-time":"2022-07-21T17:37:55Z","timestamp":1658425075000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S008525381630655X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3]]},"references-count":48,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["S008525381630655X"],"URL":"https:\/\/doi.org\/10.1016\/j.kint.2016.10.039","relation":{},"ISSN":["0085-2538"],"issn-type":[{"value":"0085-2538","type":"print"}],"subject":[],"published":{"date-parts":[[2017,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"STAT5 drives abnormal proliferation in autosomal dominant polycystic kidney disease","name":"articletitle","label":"Article Title"},{"value":"Kidney International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.kint.2016.10.039","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016, International Society of Nephrology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}